hrp0094p2-233 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

Diazoxide Responsive Congenital Hyperinsulinism

Lohiya Nikhil , Cassidy Kelly , Yung Zoe , Erlandson-Parry Karen , Wright Samantha , Gait Lucy , Didi Mohammed , Senniappan Senthil ,

Introduction: Congenital Hyperinsulism (CHI) is a common cause of recurrent and persistent hypoglycemia in the neonatal period. Diazoxide is the first line medication used for the management of CHI. We report the clinical profile and the management outcome of a large cohort of patients with diazoxide responsive CHI.Methodology: A retrospective data collection including antenatal, perinatal and postnatal clinical parameters, laboratory di...